drugset / Trial / NCT04681053

Inhaled Ivermectin and COVID-19

NCT04681053

Phase 3 Unknown 80 enrolled Mansoura University
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Coronavirus disease-19 is global healthcare crisis. Till May 20, 2020, there were approximately 4,789,205 cases and 318,789 related mortalities were identified globally. This dramatic situation led to healthcare service collapse in many countries. Each country developed its own action plan depending on healthcare expertise and the available resources. There is no definitive therapy for Coronavirus disease-19 up till now. Many current and investigational drugs are used nowadays. Recent reports suggest a beneficial role of Ivermectin in the management of Coronavirus disease-19. A notice that necessitates further clinical studies. The aim of this study is to assess the efficacy and safety of the usage of inhaled ivermectin in the management of Coronavirus disease-19.

Timeline

Start
2021-02-25
Primary completion
2021-04-30
Completion
2021-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ivermectin Small molecule 6 mg Oral

Indications